title: Micafungin as primary antifungal prophylaxis in patients presenting with acute myeloid leukemia.
abstract: OBJECTIVE
  To study the efficacy and safety of micafungin for prophylaxis of invasive fungal infections in patients undergoing induction chemotherapy for acute myeloid leukemia.
  
  
  METHODS
  A prospective observational single-center study of 41 patients from the hematology department between May 2012 and April 2015. Micafungin was administered once daily from the first day of induction chemotherapy to the end of the neutropenic phase.
  
  
  RESULTS
  Neither Candida nor Aspergillus infection was documented in our 41 patients from the first day of micafungin infusion to the end of the neutropenic phase. Patients were followed for three months after discontinuation of micafungin and none of them contracted an invasive fungal infection. Only one patient presented with grade III-IV hepatic and ionic toxicities.
  
  
  CONCLUSIONS
  Micafungin is associated with a good safety profile and is an interesting option for preventing invasive fungal infections in the high-risk population of patients presenting with hematological disorders.
authors.affiliation: Inserm, UMR1090 TAGC, 13288 Marseille, France; Aix-Marseille université, UMR1090 TAGC, 13288 Marseille, France; Service d'hématologie et de thérapie cellulaire AP-HM, hôpital de la Conception, Marseille, France.
authors.forename: G
authors.initials: G
authors.lastname: Venton
authors.affiliation: Unité pharmacie hospitalière hôpital de la Conception, Marseille, France.
authors.forename: H
authors.initials: H
authors.lastname: Adam
authors.affiliation: Inserm, UMR1090 TAGC, 13288 Marseille, France; Aix-Marseille université, UMR1090 TAGC, 13288 Marseille, France; Service d'hématologie et de thérapie cellulaire AP-HM, hôpital de la Conception, Marseille, France.
authors.forename: J
authors.initials: J
authors.lastname: Colle
authors.affiliation: Inserm, UMR1090 TAGC, 13288 Marseille, France; Aix-Marseille université, UMR1090 TAGC, 13288 Marseille, France.
authors.forename: Y
authors.initials: Y
authors.lastname: Labiad
authors.affiliation: Service d'hématologie et de thérapie cellulaire AP-HM, hôpital de la Conception, Marseille, France; UMR-911 Inserm laboratoire de toxicocinétique et pharmacocinétique, faculté de pharmacie, Marseille, France.
authors.forename: C
authors.initials: C
authors.lastname: Mercier
authors.affiliation: Service d'hématologie et de thérapie cellulaire AP-HM, hôpital de la Conception, Marseille, France.
authors.forename: V
authors.initials: V
authors.lastname: Ivanov
authors.affiliation: Laboratoire d'hématologie, AP-HM, hôpital de la Timone, Marseille, France; UMR 1062 NORT, Inserm, Marseille, France.
authors.forename: P
authors.initials: P
authors.lastname: Suchon
authors.affiliation: UMR-911 Inserm laboratoire de toxicocinétique et pharmacocinétique, faculté de pharmacie, Marseille, France; Unité pharmacie hospitalière hôpital de la Conception, Marseille, France.
authors.forename: R
authors.initials: R
authors.lastname: Fanciullino
authors.affiliation: Service d'hématologie et de thérapie cellulaire AP-HM, hôpital de la Conception, Marseille, France.
authors.forename: L
authors.initials: L
authors.lastname: Farnault
authors.affiliation: Inserm, UMR1090 TAGC, 13288 Marseille, France; Aix-Marseille université, UMR1090 TAGC, 13288 Marseille, France; Service d'hématologie et de thérapie cellulaire AP-HM, hôpital de la Conception, Marseille, France. Electronic address: regiscostello.tagc@gmail.com.
authors.forename: R
authors.initials: R
authors.lastname: Costello
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000935:Antifungal Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D001424:Bacterial Infections / Q000209:etiology; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D003630:Daunorubicin / Q000008:administration & dosage / Q000009:adverse effects; D054714:Echinocandins / Q000008:administration & dosage / Q000627:therapeutic use*; D064147:Febrile Neutropenia / Q000139:chemically induced / Q000150:complications; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage / Q000009:adverse effects; D015470:Leukemia, Myeloid, Acute / Q000150:complications*; D055666:Lipopeptides / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D000077551:Micafungin; D008875:Middle Aged; D009181:Mycoses / Q000517:prevention & control*; D011446:Prospective Studies; D055815:Young Adult
chemical_list: D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D003561:Cytarabine; D000077551:Micafungin; D015255:Idarubicin; D003630:Daunorubicin
keywords: Acute myeloid leukemia; Aspergillus; Leucémie aiguë myéloïde; Micafungin; Micafungine